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Abstract
Background and Aim
Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients on
peritoneal dialysis (PD). Hyponatremia was recently shown to be a modifiable factor that is
strongly associated with increased mortality in PD patients. However, the clinical impact of
hyponatremia on CV outcomes in these patients is unclear.
Methods
To determine whether a low serum sodium level predicts the development of CV disease,
we carried out a prospective observational study of 441 incident patients who started PD
between January 2000 and December 2005. Time-averaged serum sodium (TA-Na) levels
were determined to investigate the ability of hyponatremia to predict newly developed CV
events in these patients.
Results
During a mean follow-up of 43.2 months, 106 (24.0%) patients developed new CV events.
The cumulative incidence of new-onset CV events after the initiation of PD was significantly
higher in patients with TA-Na levels 138 mEq/L than in those with a TA-Na > 138 mEq/L.
After adjustment for multiple potentially confounding covariates, an increase in TA-Na level
was found to be associated with a significantly lower risk of CV events (subdistribution haz-
ard ratio per 1 mEq/L increase, 0.90; 95% confidence interval, 0.83–0.96; p = 0.003). Pa-
tients with a TA-Na 138 mEq/L had a 2.31-fold higher risk of suffering a CV event.
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Conclusions
These results provide evidence of a clear association between low serum sodium and new-
onset CV events after dialysis initiation in PD patients. Whether the correction of hyponatre-
mia for this indication provides additional protection for the development of CV disease in
these patients remains to be addressed in interventional studies.
Introduction
Hyponatremia is the most common electrolyte disorder and is an important marker of disease
severity and poor prognosis in several medical conditions including advanced heart failure,
liver cirrhosis, and chronic kidney disease (CKD) [1–10]. It is not clear whether hyponatremia
per se increases the risk of adverse outcomes or is simply a surrogate marker of disease severity;
however, several studies have shown a strong association between hyponatremia and high mor-
tality in patients on maintenance hemodialysis (HD) [6–9]. In a recent study [10], we showed
that hyponatremia was common in patients treated with peritoneal dialysis (PD) despite con-
tinuous dialysis therapy, and that low serum sodium concentration was an independent predic-
tor of all-cause and infection-related mortality in such patients. Of note, cardiovascular (CV)
disease is a significant risk and is among the leading causes of hospitalization and death in pa-
tients with end-stage renal disease (ESRD) on dialysis. Although CV disease is frequently pres-
ent in patients commencing dialysis, the condition may develop during long-term treatment
[11]. Thus, the identification of novel risk factors is critical for the prevention of CV disease in
patients undergoing dialysis. In our previous study [10], patients with time-averaged serum so-
dium (TA-Na) level< 137 mEq/L showed a significantly higher cumulative incidence of CV
death compared to those with a TA-Na 137; however, there was no significant relationship
between TA-Na level and CV death in the multivariable analysis [10]. This weak statistical ef-
fect found in the previous study indicates a need for further in-depth investigation to establish
the effects of low serum sodium on the CV risk with a different specific outcome such as CV
events. Therefore, the present study examined the relationship between low serum sodium con-
centration and the development of CV events in the same cohort of PD patients used in our
previous study [10].
Methods
Ethics statement
The study was carried out in accordance with the Declaration of Helsinki and approved by the
Institutional Review Board of Ilsan Hospital Clinical Trial Center. We obtained informed writ-
ten consent from all participants involved in our study.
Patients and data collection
As described in detail previously [10], the study included 549 patients who commenced PD at
Yonsei University Severance Hospital or NHIS Ilsan Hospital between January 2000 and De-
cember 2005. Patients< 18 years of age at the time of initiation of PD, or with< 6 months of
follow-up, or who had been on HD or received a kidney transplant before initiation of PD,
were excluded. Demographic and clinical data were collected at the commencement of PD.
Laboratory and dialysis-specific data obtained at the time of dialysis adequacy assessment were
considered to be baseline values and included serum sodium, potassium, and bicarbonate
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concentrations, hemoglobin, calcium, phosphorus, serum albumin, ferritin, serum C-reactive
protein (CRP) levels; Kt/V urea, percentage lean body mass (%LBM), normalized protein cata-
bolic rate (nPCR); PD ultrafiltration data; and residual glomerular filtration rate (GFR). All pa-
rameters were recorded longitudinally throughout the follow-up period and were calculated as
averages of the means of measurements taken every 3 months for laboratory data, and every 6
months for dialysis adequacy parameters. Serum sodium concentration was measured using an
electrode-based method (UniCel DXC 800; Beckman Coulter, CA, USA) and was corrected for
serum glucose level using the following formula: Corrected sodium = measured sodium
+ 0.016 × (serum glucose—100) [12].
Study outcomes
The study participants were followed-up to December 31, 2011. The primary outcome parame-
ter was the composite of the first occurrence of a fatal or nonfatal CV event, defined as coro-
nary artery disease (angioplasty, coronary artery bypass grafting, myocardial infarction, or
angina); congestive heart failure; cerebrovascular disease; and peripheral artery disease (revas-
cularization or amputation). The nature of CV event was established based on the onset of typi-
cal symptoms and signs, not based on the screening test. Congestive heart failure was defined
as clinically typical symptoms and signs, such as newly developed dyspnea, shortness of breath,
or raised jugular venous pressure combined with systolic or diastolic dysfunction by echocardi-
ography. Cerebrovascular disease was defined as cerebrovascular infarction or hemorrhage
confirmed both by typical clinical symptoms and imaging study; computed tomography or
magnetic resonance imaging.
Statistical analysis
The results are expressed as means ± standard deviations or as percentages. Data were analyzed
using Student’s t-test and the χ2 test; ANOVA was used for multiple comparisons. The Kolmo-
gorov-Smirnov test was used to determine the normality of the distribution of parameters. If
data were not normally distributed, they were expressed as the median and interquartile range
(or after log-transformation) and were compared using the Mann–Whitney test or Kruskal-
Wallis test. Time to the first occurrence of a CV event after PD initiation was estimated and
compared between groups based on the median (138.1 mEq/L) and tertiles (< 137, 137–139,
and 139 mEq/L) of TA-Na levels using the cumulative incidence competing risk method and
the K-sample test developed by Gray [13]. Data on switching to HD, kidney transplantation,
loss to follow-up, and non-CV death were censored in analysis. To determine risk factors for
the occurrence of new CV events, competing risks multivariate Cox’s regression was per-
formed, as described by Fine and Gray [14]. In all survival analyses, the Cox’s model propor-
tionality assumption was confirmed by testing of Schoenfeld residuals. The results are
expressed as a subdistribution hazard ratio (SHR) with 95% confidence intervals (CIs). A p-
value less than 0.05 was considered to indicate statistical significance. All statistical tests were
conducted using the Statistical Package for the Social Sciences, version 21.0 (SPSS Inc., Chi-
cago, IL, USA), and the R version 3.0.2 software package (http://cran.r-project.org/) including
cmprsk library.
Results
Patient characteristics
Of the initial group of 549 patients, 108 were excluded, such that 441 patients were finally in-
cluded in the study. Excluded patients were significantly older than and generally had higher
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comorbidity scores than the patients who were finally included. Other baseline characteristics
did not differ between included and excluded patients. The demographic and clinical charac-
teristics of the 441 study participants were detailed in previous our report Table 1 [10]. The pa-
tients who suffered from at least one among the four CV events before PD initiation were 123
(27.9%). Table 1 summarizes patient characteristics of previous CV disease and echocardio-
graphic findings of parameters associated with hydration at initiation of PD according to
TA-Na level tertiles, and showed no significant association between the type of previous CV
disease or echocardiographic parameters and the TA-Na level.
Hyponatremia as a predictor of a new-onset cardiovascular event
During a mean follow-up time of 43.2 months, 106 (24.0%) patients developed new CV events
including coronary artery disease (56 patients, 52.8%), cerebrovascular disease (26 patients,
24.5%), congestive heart failure (13 patients, 12.3%), and peripheral artery disease (11 patients,
10.4%). The cumulative incidence of new-onset CV events after initiation of PD was signifi-
cantly higher in patients with lower TA-Na levels than in those with a TA-Na> 138 mEq/L
(median) or a TA-Na 139 mEq/L (highest tertile), respectively (Fig 1).
A higher TA-Na was associated with a lower risk of a new CV event (Table 2). Models fea-
turing various adjustments showed that this association was both significant and consistent.
Using serum TA-Na as a continuous variable, the SHR for new-onset CV events was 0.90 per 1
mEq/L rise in TA-Na (95% CI, 0.83–0.96; p = 0.003), indicating that a higher TA-Na was sig-
nificantly associated with a decreased risk of developing new CV events. In addition, patients
with a TA-Na 138 mEq/L had a 2.31-fold higher risk of CV events than those with a
TA-Na> 138 mEq/L. First-order interaction terms between covariates were determined for all
models, but we found no evidence of any interaction between these covariates.
To rule out that the results were influenced by the presence of previous CV disease, we re-
peated all competing risk analyses in subgroups of the 318 patients without previous CV dis-
ease. In this additional analysis, the observed effects in the various subgroups were similar to
those in the crude analyses (data not shown). Finally, we also conducted subgroup analyses to
evaluate the efficacy of serum sodium level as a predictor of cause-specific CV events. The un-
adjusted model revealed an increased risk of coronary artery disease (p = 0.017) in patients
Table 1. Patient characteristics at baseline.
Time-averaged serum sodium (mEq/L)
< 137 137 to < 139 139 p for trend
Previous cardiovascular disease (n = 441) 48 (33.1) 41 (27.7) 134(23.0) 0.054
Coronary artery disease 27 (18.6) 24 (16.2) 19 (12.8) 0.176
Congestive heart failure 15 (10.3) 12 (8.1) 8 (5.4) 0.118
Cerebrovascular disease 24 (16.6) 25 (16.9) 20 (13.5) 0.473
Peripheral artey disease 9 (6.2) 1 (0.7) 5 (3.4) 0.187
Echocardiographic ﬁndings (n = 98)
LA volume index (mL/m2) 32.1±11.1 30.4±17.6 27.8±8.9 0.177
LV end-diastolic diameter (mm) 50.0±7.4 49.3±4.8 51.9±5.4 0.137
LV mass index (g/m2) 118.8±36.2 117.6±36.9 120.0±36.9 0.884
TR peak velocity (m/sec) 2.32±0.42 2.29±0.37 2.31±0.36 0.916
Values are given as numbers of patients (percentage); Values for continuous variables are given as mean ± standard deviation. LA, left atrial; LV, left
ventricular; TR, tricuspid regurgitation.
doi:10.1371/journal.pone.0129480.t001
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with TA-Na 138 mEq/L; however, the association was not significant after adjustment. Inter-
estingly, all new-onset peripheral artery disease occurred in patients with TA-Na 138 mEq/
L. In contrast, neither the unadjusted or adjusted analyses revealed any association between
low serum sodium levels and the risks of congestive heart failure or cerebrovascular disease.
Cumulative incidence estimates of the other outcomes
The competing risk analysis also allows the calculation of the cumulative incidence of the other
possible outcomes, shown in Fig 2 and summarized in Table 3. Non-CV death before any new-
onset CV event was the second-rank outcome (cumulative incidence of 0.30 at 120 months),
followed by transfer to HD (0.18), and renal transplantation (0.07) before a CV event (Fig 2).
Discussion
In this study, we investigated the relationship between serum sodium levels and the occurrence
of new-onset CV events in our cohort of patients with ESRD undergoing PD. We showed that a
low TA-Na level independently predicted new-onset CV events, suggesting that hyponatremia is
a potential predictor of adverse outcomes in PD patients. Thus, patients with low sodium levels
should be receive appropriate treatment to prevent CV disease even after initiation of dialysis.
Hyponatremia has long been described as a predictor of CV mortality and morbidity in se-
verely ill patients, especially in those with heart failure, myocardial infarction, stroke, or cirrho-
sis [3, 4, 15–17]. Several recent studies, including ours, have shown that hyponatremia is
common among patients with ESRD and is strongly associated with poor clinical outcomes [6–
10]. However, these studies focused primarily on mortality risk. Patients with ESRD who are
Fig 1. The cumulative incidence curves for the first occurrence of a cardiovascular event after the initiation of peritoneal dialysis between groups
defined according to the median (A) and tertile (B) of the time-averaged serum sodium (TA-Na) levels.
doi:10.1371/journal.pone.0129480.g001
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on maintenance dialysis are at an increased risk of mortality; moreover, CV disease is the lead-
ing cause of hospitalization and death in patients on PD [11]. Nonetheless, few studies have in-
vestigated the association between serum sodium levels and the risk of developing CV disease
in patients on PD.
Table 2. Multivariable Cox regression analyses for the risk of new-onset cardiovascular events.
Model 1 Model 2 Model 3
SHR (95% CI) p SHR (95% CI) p SHR (95% CI) p
Continuous model
(per 1 mEq/L TA-Na increase) 0.89 (0.83–0.95) <0.001 0.89 (0.83–0.95) <0.001 0.90 (0.83–0.96) 0.003
Categorical model
(Median)
TA-Na  138 mEq/L 2.27 (1.65–3.68) <0.001 2.57 (1.73–3.82) <0.001 2.31 (1.49–3.58) <0.001
TA-Na > 138 mEq/L 1.00 (reference) 1.00 (reference) 1.00 (reference)
(Tertile)
TA-Na < 137 mEq/L 2.07 (1.29–3.32) 0.003 2.22 (1.39–3.56) 0.001 1.94 (1.17–3.21) 0.010
137 mEq/L  TA-Na <139 mEq/L 1.39 (0.86–2.26) 0.180 1.43 (0.89–2.32) 0.140 1.10 (0.65–1.88) 0.720
TA-Na  139 mEq/L 1.00 (reference) 1.00 (reference) 1.00 (reference)
TA-Na, time-averaged serum sodium; SHR, subdistribution hazard ratio; CI, conﬁdence interval. Adjustments in model 1: Demographic and clinical
parameters including sex, body mass index, Charlson Comorbidity Index score, anti-hypertensive medications; model 2: model 1 plus dialysis-speciﬁc
parameters including use of icodextrin, use of high glucose dialysate, peritoneal dialysis ultraﬁltration, total Kt/V urea, normalized protein catabolic rate,
and percentage of lean body mass; model 3: model 2 plus laboratory parameters including serum hemoglobin, serum albumin, calcium, phosphorus,
potassium, bicarbonate, serum ferritin, C-reactive protein, and residual renal function.
doi:10.1371/journal.pone.0129480.t002
Fig 2. The cumulative incidence curves for a new-onset cardiovascular event and other outcomes.
CVE, cardiovascular event.
doi:10.1371/journal.pone.0129480.g002
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Our results indicate that a low serum sodium concentration is significantly associated with
an increased risk of new CV events in patients undergoing PD. Even after vigorous adjustments
for potentially multiple confounding covariates, including demographic, laboratory, and dialy-
sis-specific data, an increase in the TA-Na level of 1 mEq/L was still associated with a 10% de-
creased risk of newly developing a CV event. Moreover, patients with a TA-Na level 138
mEq/L had a 2.31-fold higher risk of CV events than patients with a TA-Na level> 138 mEq/
L, indicating the significant association between higher serum sodium levels and a lower risk of
a newly developed CV event.
The mechanisms underlying the increased risk of CV events in PD patients with low serum
sodium levels are complex and poorly understood. Previous studies have focused on patients
with chronic heart failure [18–22], in which hyponatremia was shown to be related to neuro-
hormonal activation, such as the non-osmotic release of vasopressin [20], activation of the
renin-angiotensin system [21], and increased catecholamine production [22]. However, any
Table 3. Cumulative incidence of a new-onset cardiovascular event and other outcomes.
Duration of follow up (months) 24 48 72 96 120
(Median)
CVE
TA-Na  138 mEq/L 0.14 0.28 0.40 0.43 0.45
TA-Na > 138 mEq/L 0.07 0.10 0.18 0.21 0.23
Non-cardiovascular death before CVE
TA-Na  138 mEq/L 0.09 0.19 0.22 0.24 0.27
TA-Na > 138 mEq/L 0.07 0.19 0.27 0.31 0.34
Transfer to hemodialysis before CVE
TA-Na  138 mEq/L 0.06 0.10 0.15 0.15 0.17
TA-Na > 138 mEq/L 0.02 0.09 0.11 0.15 0.19
Transplantation before CVE
TA-Na  138 mEq/L 0.00 0.03 0.04 0.04 0.06
TA-Na > 138 mEq/L 0.03 0.05 0.06 0.07 0.09
(Tertile)
CVE
TA-Na < 137 mEq/L 0.16 0.29 0.38 0.41 0.46
137 mEq/L  TA-Na <139 mEq/L 0.08 0.17 0.30 0.33 0.33
TA-Na  139 mEq/L 0.08 0.12 0.19 0.22 0.25
Non-cardiovascular death before CVE
TA-Na < 137 mEq/L 0.11 0.21 0.25 0.25 0.25
137 mEq/L  TA-Na <139 mEq/L 0.07 0.16 0.20 0.24 0.27
TA-Na  139 mEq/L 0.07 0.18 0.27 0.32 0.36
Transfer to hemodialysis before CVE
TA-Na < 137 mEq/L 0.06 0.11 0.15 0.15 0.15
137 mEq/L  TA-Na <139 mEq/L 0.04 0.10 0.13 0.15 0.19
TA-Na  139 mEq/L 0.02 0.08 0.11 0.15 0.19
Transplantation before CVE
TA-Na < 137 mEq/L 0.00 0.05 0.05 0.05 0.08
137 mEq/L  TA-Na <139 mEq/L 0.01 0.03 0.04 0.04 0.04
TA-Na  139 mEq/L 0.04 0.05 0.06 0.08 0.11
CVE, cardiovascular event;
TA-Na, time-averaged serum sodium.
doi:10.1371/journal.pone.0129480.t003
Hyponatremia as a Predictor of Cardiovascular Events
PLOS ONE | DOI:10.1371/journal.pone.0129480 June 8, 2015 7 / 10
relationship between neurohormonal activation and adverse outcomes in patients undergoing
PD is largely unknown [23]; thus, it is unclear whether mechanisms contributing to the devel-
opment of chronic hyponatremia in patients with normal GFRs can explain our findings. Fu-
ture studies are needed to evaluate the effect of neurohormonal activation on the development
of hyponatremia and CV disease in PD patients. Moreover, several factors associated with the
development of hyponatremia in patients with ESRD, such as reduction in residual renal func-
tion, protein-energy wasting, and chronic inflammation are likely to underlie the high risk of
CV events in patients undergoing PD [24–27]. Furthermore, these factors are well-established
predictors of mortality and have been shown to play pivotal roles in the development of CV
disease in patients on dialysis [28–31]. Taken together, the above mechanisms may explain the
association between hyponatremia and the increased CV risk in patients undergoing PD.
Our study had several limitations. As an observational study, the causality of our findings
needs further confirmation. Furthermore, it is unknown whether the correction of hyponatre-
mia can improve clinical outcomes in dialysis patients. Moreover, because of our relatively
small sample size, we were not able to determine conclusively the effect of hyponatremia on
cause-specific CV disease. Finally, given that the mechanism underlying hyponatremia is likely
multifactorial [24], additional information, on nutritional status and neurohormonal activa-
tion, is needed to explain the development of hyponatremia in patients with CKD. In particu-
lar, lack of data regarding volume status is important drawback, despite baseline
echocardiographic parameters related to the state of hydration were partly presented in 98 pa-
tients; a more judicious approach using the objective techniques such as echocardiographic pa-
rameters, serum biomarkers, and bioelectrical impedance analysis might be warranted to assess
fluid status in hyponatremic PD patients. Nonetheless, this study showed that a low TA-Na
level independently predicted the development of new-onset CV events after dialysis initiation,
even after extensive adjustment for demographic, clinical, laboratory, and dialysis-specific co-
variates. Our robust findings suggest that hyponatremia portends a poor prognosis; thus, in
clinical practice, physicians should be meticulous in treating both the electrolyte imbalance
and the underlying disease.
Conclusion
In conclusion, our study showed that a low serum sodium concentration is an independent
predictor of new-onset CV events in PD patients. Whether the correction of hyponatremia in
this setting provides additional protection against the development of CV events will need to
be addressed in interventional studies.
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